Drug intelligence / Profile preview

Q-Pan H5N8

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Q-Pan H5N8 is an adjuvanted monovalent influenza vaccine candidate developed by GSK for pandemic preparedness against the H5N8 subtype of Influenza A virus. The vaccine is based on the A/Astrakhan/3212/2020-like strain and incorporates GSK's proprietary AS03 adjuvant system, an oil-in-water emulsion containing alpha-tocopherol and squalene. AS03 is designed to enhance the magnitude and breadth of the immune response, potentially allowing for dose-sparing and improved protection against drifted strains. The vaccine is currently being evaluated in Phase I/II clinical trials to assess its safety and immunogenicity in adults aged 18 and older, including the elderly population.

Other names: Monovalent influenza H5N8 vaccineA/Astrakhan/3212/2020-like (H5N8) virus vaccine

Targets

Neuraminidase

Beyond the preview

Go deeper on Q-Pan H5N8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q-Pan H5N8.

Explore the full profile